Risk Factors
424 articles
Gil Bashe
Our health system is hard to navigate — sometimes the sectors seem at odds. But, patients expect that each piece of the medical puzzle – physician, provider, payer, pharma and policy – will focus on their wellbeing. Through my 30+ years in health, I’ve believed that communication with the patient is a crucial part of […]
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Testing a Different Approach to Pancreatic Cancer Treatment
A drug that is epigenetic therapy, which alters how DNA behaves, is being tested in a clinical trial for pancreatic cancer.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.